Study on Combining Immunotherapy and Radiation Therapy for Stage IV Cancers

Inclusion Criteria

• Have a confirmed diagnosis of advanced or stage IV cancer in areas like the head and neck, lungs, cervix, esophagus, stomach, or gastroesophageal junction, with at least 6 cancer sites eligible for focused radiation therapy (SBRT).
• Eligible for immunotherapy based on FDA-approved guidelines.
• If previously treated with chemotherapy or radiation, it must have been completed more than 21 days before starting the study treatment.
• Currently on first-line immunotherapy-based treatments.
• Meet specific criteria for certain cancers, such as PD-L1 testing scores for lung, cervical, gastric, esophageal, or gastroesophageal cancers.
• Have a performance status score of 0 or 1, indicating full activity or some restriction in strenuous activities.
• Life expectancy of at least 6 months.
• Adequate organ and bone marrow function as determined by specific lab tests.
• No other active cancers, except for certain skin cancers or cervical cancer that have been treated and disease-free for 3 years.
• Women must not be pregnant or nursing and must agree to use effective contraception during the study.
• Ability to understand and willingness to sign informed consent.

Exclusion Criteria

• Have fewer than 6 cancer sites eligible for SBRT.
• Ineligible for immune checkpoint inhibitors based on specific guidelines.
• More than 7 cancer sites in a single organ.
• Certain conditions like liver cirrhosis that prevent SBRT to the liver.
• Recent major surgery or significant injury within 14 days before joining the study.
• Active serious infections or non-healing wounds.
• Uncontrolled health issues like heart failure, recent heart attacks, or high blood pressure.
• Known infections like HIV or chronic hepatitis B or C.
• Recent receipt of live vaccines within 30 days before starting the study treatment.
• Women and minorities are encouraged to participate, consistent with NIH policy.